Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Medical Health Institute vs Obu Health

Medical Health Institute
Graded #469

Lower grade

vs+6.600000000000001
Obu Health
Graded #332

Higher grade

The verdict

Obu Health takes it — 59.9/100 to 53.3/100.

Obu Health grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. Obu Health is a Las Vegas-based multi-product telehealth platform offering compounded semaglutide from $190/month and compounded tirzepatide from $239/month, plus NAD+ and sermorelin add-ons.

We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.

Factor by factor

The same six graded dimensions, side by side. See the methodology.

Cost valueMedical Health Institute +1
45
44
Dose & formulationObu Health +24
40
64
Clinical oversightObu Health +15
69
84
Labs & monitoringObu Health +1
52
53
FulfillmentObu Health +7
67
74
Contract termsMedical Health Institute +24
55
31
Medical Health Institute · left barObu Health · right bar

The numbers

MetricMedical Health InstituteObu Health
WeighScore53.3/10059.9/100
GradeCC
Scorecard rank#469#332
SemaglutideNot disclosed$190/mo (starting dose, plus a separate fee, compounded)
TirzepatideNot disclosed$239/mo (starting dose, plus a separate fee, compounded)
CoverageCoverage not publishedCoverage not published
Brand-name accessCompounded onlyCompounded only
Oral / sublingualInjection onlyInjection only
Medical Health Institute

Graded #469 · C

Strengths

  • Operating entity disclosed: Medical Health Institute, LLC, with full Pinecrest, FL address and phone
  • Named medical director (Amy Wecker, MD) plus four more named clinicians on the about page
  • Three care pathways with starting-price anchors: $99 TRT / $129 peptides / $149 weight-loss
  • LegitScript Certified with a footer verification link
  • HIPAA compliance claimed

Where it loses points

  • GLP-1 medication options (semaglutide vs tirzepatide; compounded vs brand) not shown — gated behind the intake funnel
  • Pharmacy partner not named — only generic 'FDA-regulated facilities' language
  • State availability not disclosed
  • Several subpages (/weight-loss, /pricing, /products, /faq) returned server errors during verification
  • FDA has issued this company a warning letter; the letter is public in FDA's warning-letter database
Obu Health

Graded #332 · C

Strengths

  • LegitScript-certified with publicly displayed ID (44206977)
  • Two named 503A compounding-pharmacy partners (Manifest Pharmacy SC + RX Compounding Store FL) — transparency above category baseline
  • Lower advertised semaglutide starting price ($190) than most multi-product peer platforms
  • Multi-product offering (GLP-1s + NAD+ + sermorelin + generic ED + birth control) for single-platform users
  • 24-hour US board-certified physician response window

Where it loses points

  • Per-dose pricing tiers not transparently published on product pages — only 'starting from' prices visible
  • No explicit state-coverage list disclosed; FAQ confirms restrictions exist 'based on state' without enumeration
  • Medical director not named publicly
  • No published consultation fee disclosure — unclear whether physician visit is included in medication price
  • All sales final per FAQ ('Federal and State law do not allow medication returns')

Also worth a look

Neither is our top-graded pick — CoreAge Rx leads the scorecard

Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard